BACKGROUND: 3-bromopyruvate is an alkylating agent with antitumor activity. It is currently believed that blockade of adenosine triphosphate production from glycolysis and mitochondria is the primary mechanism responsible for this antitumor effect. The current studies uncovered a new and novel mechanism for the antitumor activity of 3-bromopyruvate. METHODS: The transport of 3-bromopyruvate by sodium-coupled monocarboxylate transporter SMCT1 (SLC5A8), a tumor suppressor and a sodium (Na+)-coupled, electrogenic transporter for short-chain monocarboxylates, was studied using a mammalian cell expression and the Xenopus laevis oocyte expression systems. The effect of 3-bromopyruvate on histone deacetylases (HDACs) was monitored using the lysate of the human breast cancer cell line MCF7 and human recombinant HDAC isoforms as the enzyme sources. Cell viability was monitored by fluorescence-activated cell-sorting analysis and colony-formation assay. The acetylation status of histone H4 was evaluated by Western blot analysis. RESULTS: 3-Bromopyruvate is a transportable substrate for SLC5A8, and that transport process is Na+-coupled and electrogenic. MCF7 cells did not express SLC5A8 and were not affected by 3-bromopyruvate. However, when transfected with SLC5A8 or treated with inhibitors of DNA methylation, these cells underwent apoptosis in the presence of 3-bromopyruvate. This cell death was associated with the inhibition of HDAC1/HDAC3. Studies with different isoforms of human recombinant HDACs identified HDAC1 and HDAC3 as the targets for 3-bromopyruvate. CONCLUSIONS: 3-Bromopyruvate was transported into cells actively through the tumor suppressor SLC5A8, and the process was energized by an electrochemical Na+ gradient. Ectopic expression of the transporter in MCF7 cells led to apoptosis, and the mechanism involved the inhibition of HDAC1/HDAC3. Copyright (c) 2009 American Cancer Society.
BACKGROUND:3-bromopyruvate is an alkylating agent with antitumor activity. It is currently believed that blockade of adenosine triphosphate production from glycolysis and mitochondria is the primary mechanism responsible for this antitumor effect. The current studies uncovered a new and novel mechanism for the antitumor activity of 3-bromopyruvate. METHODS: The transport of 3-bromopyruvate by sodium-coupled monocarboxylate transporter SMCT1 (SLC5A8), a tumor suppressor and a sodium (Na+)-coupled, electrogenic transporter for short-chain monocarboxylates, was studied using a mammalian cell expression and the Xenopus laevis oocyte expression systems. The effect of 3-bromopyruvate on histone deacetylases (HDACs) was monitored using the lysate of the humanbreast cancer cell line MCF7 and human recombinant HDAC isoforms as the enzyme sources. Cell viability was monitored by fluorescence-activated cell-sorting analysis and colony-formation assay. The acetylation status of histone H4 was evaluated by Western blot analysis. RESULTS:3-Bromopyruvate is a transportable substrate for SLC5A8, and that transport process is Na+-coupled and electrogenic. MCF7 cells did not express SLC5A8 and were not affected by 3-bromopyruvate. However, when transfected with SLC5A8 or treated with inhibitors of DNA methylation, these cells underwent apoptosis in the presence of 3-bromopyruvate. This cell death was associated with the inhibition of HDAC1/HDAC3. Studies with different isoforms of human recombinant HDACs identified HDAC1 and HDAC3 as the targets for 3-bromopyruvate. CONCLUSIONS:3-Bromopyruvate was transported into cells actively through the tumor suppressor SLC5A8, and the process was energized by an electrochemical Na+ gradient. Ectopic expression of the transporter in MCF7 cells led to apoptosis, and the mechanism involved the inhibition of HDAC1/HDAC3. Copyright (c) 2009 American Cancer Society.
Authors: Daryl C Drummond; Charles O Noble; Dmitri B Kirpotin; Zexiong Guo; Gary K Scott; Christopher C Benz Journal: Annu Rev Pharmacol Toxicol Date: 2005 Impact factor: 13.820
Authors: Young H Ko; Barbara L Smith; Yuchuan Wang; Martin G Pomper; David A Rini; Michael S Torbenson; Joanne Hullihen; Peter L Pedersen Journal: Biochem Biophys Res Commun Date: 2004-11-05 Impact factor: 3.575
Authors: S M El Sayed; R M Abou El-Magd; Y Shishido; S P Chung; T H Diem; T Sakai; H Watanabe; S Kagami; K Fukui Journal: J Bioenerg Biomembr Date: 2012-02-09 Impact factor: 2.945
Authors: Adriana López-Barradas; Tania González-Cid; Norma Vázquez; Marisol Gavi-Maza; Adriana Reyes-Camacho; Laura A Velázquez-Villegas; Victoria Ramírez; Kambiz Zandi-Nejad; David B Mount; Nimbe Torres; Armando R Tovar; Michael F Romero; Gerardo Gamba; Consuelo Plata Journal: Am J Physiol Cell Physiol Date: 2016-08-03 Impact factor: 4.249
Authors: Jong Y Park; Donghwa Kim; Mihi Yang; Hyun Y Park; Sang Haak Lee; Maria Rincon; Jenny Kreahling; Christoph Plass; Dominic J Smiraglia; Melvyn S Tockman; Seung Joon Kim Journal: Lung Cancer Date: 2012-12-27 Impact factor: 5.705
Authors: James Helm; Domenico Coppola; Vadivel Ganapathy; Mark Lloyd; Barbara A Centeno; Dung-Tsa Chen; Mokenge P Malafa; Jong Y Park Journal: Pancreas Date: 2012-08 Impact factor: 3.327
Authors: J Azevedo-Silva; O Queirós; F Baltazar; S Ułaszewski; A Goffeau; Y H Ko; P L Pedersen; A Preto; M Casal Journal: J Bioenerg Biomembr Date: 2016-07-25 Impact factor: 2.945